Duvelisib联合利妥昔单抗或苯达莫司汀/利妥昔单抗治疗NHL或CLL的试验
这项1期研究评估了Duvelisib联合利妥昔单抗或苯达莫司汀/利妥昔单抗在复发/难治性非霍奇金淋巴瘤(NHL)和慢性淋巴细胞白血病(CLL)患者中的安全性及疗效。
要点
- Duvelisib联合利妥昔单抗或苯达莫司汀/利妥昔单抗未增加超出单药已知安全谱的毒性。
- 总缓解率71.8%,中位无进展生存期13.7个月,30个月总生存概率62%。
- 基于单药1期研究IPI-145-02,扩展期Duvelisib剂量选择为25 mg每日两次。
核心结论
- Duvelisib联合利妥昔单抗或苯达莫司汀/利妥昔单抗在复发/难治性NHL和CLL中显示出抗肿瘤活性,且毒性未超出各单药已知范围。
- 需进一步研究确定这些联合方案是否改善疗效。
研究设计与样本
- 1期研究,纳入复发/难治性NHL和CLL患者,扩展期各臂按疾病特异性队列入组以评估疗效。
- 第1臂:利妥昔单抗375 mg/m2 IV每周,两个4周周期,联合Duvelisib直至进展/不耐受。
- 第2臂:利妥昔单抗375 mg/m2 IV第1天,苯达莫司汀90 mg/m2 IV(NHL)或70 mg/m2 IV(CLL)第1-2天,共6周期,联合Duvelisib直至进展/不耐受。
- 剂量递增阶段测试Duvelisib 50 mg和75 mg每日两次;扩展期剂量为25 mg每日两次,基于单药1期研究IPI-145-02。
主要发现
- 最常见不良事件为中性粒细胞减少(47.7%)、疲劳(41.3%)和皮疹(41.3%)。
- 总缓解率71.8%。
- 中位无进展生存期13.7个月。
- 中位总生存期未达到,30个月总生存概率62%。
关键数值与推荐
- Duvelisib扩展期剂量为25 mg每日两次。
- 利妥昔单抗剂量为375 mg/m2 IV。
- 苯达莫司汀剂量为90 mg/m2 IV(NHL)或70 mg/m2 IV(CLL)。
临床怎么用
- 对于复发/难治性NHL和CLL,Duvelisib联合利妥昔单抗或苯达莫司汀/利妥昔单抗是一种可选方案,但需进一步研究确认疗效优势。
- 联合治疗时需监测中性粒细胞减少、疲劳和皮疹等不良事件。
局限性
- 需进一步研究确定联合方案是否改善疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duvelisib, a potent δ- and γ-PI3K inhibitor, is a potential therapeutic for hematologic malignancies. Rituximab and bendamustine have demonstrated activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Combining duvelisib with either rituximab alone or rituximab and bendamustine may improve response rates and remission durability. We conducted this Phase one study in relapsed/refractory NHL and CLL patients. During expansion, each arm enrolled to disease-specific cohorts to assess efficacy. Arm one received rituximab 375 mg/m2 IV weekly for two 4-week cycles plus duvelisib until progression/intolerance. Arm two received rituximab 375 mg/m2 IV Day one, bendamustine 90 mg/m2 IV (NHL patients) or 70 mg/m2 IV (CLL patients) Days one-two for six cycles, plus duvelisib until progression/intolerance. Duvelisib doses of 50 mg and 75 mg BID were tested during dose escalation. Forty-six patients (27 NHL, 19 CLL) were treated. The adverse events of the drug combinations were consistent with single agent toxicities. The most common AEs were neutropenia (47.7%), fatigue (41.3%), and rash (41.3%). A duvelisib expansion dose of 25 mg BID was chosen based on the monotherapy phase one study, IPI-145-02, which confirmed that dose for further clinical development. Overall response rate was 71.8%. Median progression-free survival was 13.7 months. Median overall survival has not been reached, but 30-month overall survival probability was 62%. Duvelisib combined with rituximab, or bendamustine and rituximab did not appear to increase toxicities beyond the known safety profile of the individual agents. Further study is needed to determine if these combinations improve efficacy.
引用
- Flinn IW, Cherry MA, Maris MB, et al. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Am J Hematol. 2019. PMID: 31490009. doi:10.1002/ajh.25634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。